Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin

Circulation

Volumn 110, Issue 12, 2004, Pages 1658-1663

  Kovacs, Michael J ^a   Kearon, C ^b   Rodger, M ^c   Anderson, D R ^d   Turpie, A G G ^b   Bates, S M ^e   Desjardins, L ^f   Douketis, J ^g   Kahn, S R ^h   Solymoss, S ⁱ   Wells, P S ^c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ ST MARY S HOSPITAL   (Canada)

Author keywords

Blood vessel prosthesis; Bridging therapy; Fibrillation; Heparin; Low molecular weight

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ARTERY EMBOLISM; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; ATRIAL FIBRILLATION; BLOOD LOSS, SURGICAL; COHORT STUDIES; DALTEPARIN; FEASIBILITY STUDIES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTRAOPERATIVE COMPLICATIONS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK; SURGICAL PROCEDURES, ELECTIVE; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 20844440527     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000142859.77578.C9     Document Type: Article

References (24)

1. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-1511.
2. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med. 1996;335:407-416.
3. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635-641.
4. Douketis JD, Crowther MA, Cherian SS, et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest. 1999;116: 1240-1246.
5. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. Am Heart J. 1978;96:163-165.
6. Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy with mechanical and biological prosthetic heart valves. Chest. 1995;108: 371S-379S.
7. Madura JA, Rookstool M, Wease G. The management of patients on chronic warfarin therapy undergoing subsequent procedures. Am Surg. 1994;60:542-546.
8. Eckman MH, Beshasky JR, Durand-Zalenski I, et al. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. JAMA. 1990;263:1513-1521.
9. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Intern Med. 1998;158: 1809-1812.
10. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
11. Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. N Engl J Med. 1997;337:657-662.
12. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163: 901-908.
13. Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med. 2003;163:881-883.
14. Turpie AG, Antman EM. Low-molecular-weight heparins in the treatment of acute coronary syndromes. Arch Intern Med. 2001;161: 1484-1490.
15. Tinmouth A, Morrow BH, Cruickshank MK, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001;35:669-674.
16. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;122:40-42.
17. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857-872.
18. Van Es RF, Jonker JJ, Verheugt FW, et al, for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360: 109-113.
19. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
20. Spandorfer JM, Lynch S, Weitz HH, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999;84:478-480, A10.
21. Ferreira I, Dos L, Tornos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart. 2003;89:527-530.
22. Berge E, Abdelnoor M, Nakstad PH, et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study: HAEST Study Group: Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355:1205-1210.
23. Ginsberg JS, Chan WS, Bates SM, et al. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med. 2003;163: 694-698.
24. Kearon C. Management of anticoagulation before and after elective surgery. Hematology. 2003;:528-539.